MedTrace Logo

BAP1 Testing in Instance Choroidal Nevi or Uveal Melanoma

NCT01925599 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 133

Last updated 2021-03-26

No results posted yet for this study

Summary

The BAP1 trial will examine the blood of patients diagnosed with choroidal nevi or uveal melanoma for a germline BAP1 mutation and other genetic markers associated with developing malignancy as well as additional sequencing of the uveal melanoma genome.

Conditions

  • Choroidal Nevi, Uveal Melanoma

Sponsors & Collaborators

  • Amy C Schefler, MD

    lead OTHER

Principal Investigators

  • Amy C. Schefler, MD · Retina Consultants Houston

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-07-31
Primary Completion
2022-01-31
Completion
2022-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01925599 on ClinicalTrials.gov